Loading...
Market
Which region will have highest sales growth for subcutaneous Nivolumab by end of 2025?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Bristol Myers Squibb's regional sales reports
Story
FDA Approves Subcutaneous Nivolumab by Bristol Myers Squibb for Advanced or Metastatic Solid Tumors
Dec 27, 2024, 04:10 PM
The U.S. Food and Drug Administration (FDA) has approved a subcutaneous formulation of Nivolumab, also known as Opdivo, for use in patients with advanced or metastatic solid tumors. This approval, announced on December 27, 2024, allows for an injectable version of the drug, which is manufactured by Bristol Myers Squibb. The approval is expected to enhance treatment options for patients suffering from various types of cancer, including lung and gastrointestinal cancers, as well as breast cancer, where recent studies have indicated the drug's efficacy in combination with other therapies. The FDA's decision follows a series of discussions and presentations at recent oncology conferences, highlighting the importance of personalized cancer care and the role of biomarkers in treatment decisions.
View original story
Similar markets
Other • 25%
AstraZeneca • 25%
Roche • 25%
Johnson & Johnson • 25%
Southeast Asia • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Latin America • 25%
Africa • 25%
North America • 25%
Europe • 25%
Asia • 25%
Latin America • 25%
Southeast Asia • 25%
South Asia • 25%
Sub-Saharan Africa • 25%
United States • 25%
Other • 25%
China • 25%
European Union • 25%
Other • 25%
Europe • 25%
Asia • 25%
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
North America • 25%
North America • 25%
Other • 25%
Asia • 25%
Europe • 25%
Other • 25%
South America • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
Europe • 25%
Other regions • 25%
Asia-Pacific • 25%
North America • 25%
Western Pacific • 25%
South-East Asia • 25%
Sub-Saharan Africa • 25%
Latin America • 25%
Asia-Pacific • 25%
North America • 25%
Europe • 25%
Other regions • 25%